Navigation Links
Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
Date:10/22/2008

creased 8% due primarily to higher sales of livestock, poultry and companion animal products and the favorable impact of foreign exchange, which were offset, in part, by lower sales of equine products. Excluding the favorable impact of foreign exchange, worldwide Animal Health net revenue increased 9% for the third quarter of 2008 and 3% for the first nine months of 2008.

R&D Update

Later this month, Wyeth will present Phase 3 pediatric data for its investigational 13-valent pneumococcal conjugate vaccine PREVNAR 13 at the meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America in Washington, D.C. The Company expects to complete its U.S. filing for pediatric use of the vaccine in the first quarter of 2009, with other pediatric global filings expected at the same time, or possibly earlier. Prevnar 13 is also being studied in Phase 3 global clinical trials in adults.

Productivity Initiative

In the 2008 third quarter, the Company continued to realize the benefits of Project Impact, a company-wide program designed to initially address short-term fiscal challenges, particularly the significant loss of sales and profits resulting from the launch of generic versions of Protonix. Longer-term, Project Impact will include strategic actions that will fundamentally change how the Company conducts business as it adapts to the continuously changing business climate.

When fully implemented, we expect this initiative to generate annual cost savings in a range of $1.0 to $1.5 billion.

The charges for the third quarter and first nine months of 2008 included expenses of $115.2 million and $456.1 million, respectively, primarily for severance and other employee-related costs associated with a reduction in workforce of approximately 6%. The expenses in connection with the productivity initiative for the first nine months of 2008 were offset, in part, by a $104.7 million gain on the
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
2. Wyeth Announces Increase in Common Stock Dividend
3. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
4. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
5. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
6. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
7. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
8. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
9. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
10. Wyeth Declares Common and Preferred Stock Dividends
11. Wyeth Pharmaceuticals Announces Organizational Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative ... information about dual arch impressions on its dental blog. ... the blog entry serves up a list of tips to ... demonstration by Dr. David Little as he crafts a porcelain ...
(Date:1/14/2014)... 14, 2014 BioMedomics, Inc. , a ... diagnostic platforms and novel disease specific POC tests, announced today ... netting a total of $690,000. The investment is from private ... company. This group of private investors has significant successful experience ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2BioMedomics, Inc. Closes $690K Round of Financing 2
... Call on Friday, March 13, 2009 at 8:30am ... Inc. (Nasdaq: KERX ), a biopharmaceutical ... of medically important, novel pharmaceutical products for the ... cancer (the "Company"), today announced its results for ...
... Burrill & Company Collaborating on Strategic Next Steps ... Developer Tower Investments, LLC ("Tower"), and San Francisco-based ... announced a formal partnership with aims of advancing ... and funding related to the "shovel-ready" BioBusiness Park ...
... , - ThromboGenics Reports Pre-Tax Profit ... ThromboGenics NV (Euronext Brussels: THR), a biotechnology company,focused on the ... difference to patient care in a number of important therapeutic,areas, ... for the,full year ending December 31, 2008. , ...
Cached Biology Technology:Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 6Elk Run Developers Announce Partnership with Leading Life Sciences Firm 2Elk Run Developers Announce Partnership with Leading Life Sciences Firm 3Elk Run Developers Announce Partnership with Leading Life Sciences Firm 4ThromboGenics Announces Business Update and 2008 Full Year Results 2ThromboGenics Announces Business Update and 2008 Full Year Results 3ThromboGenics Announces Business Update and 2008 Full Year Results 4ThromboGenics Announces Business Update and 2008 Full Year Results 5ThromboGenics Announces Business Update and 2008 Full Year Results 6
(Date:4/20/2014)... gift of germsgerms that help to kick-start the ... off infection, may paradoxically interrupt a newborn,s own ... to dangerous pathogens. , A new animal ... of Philadelphia (CHOP) sheds light on immunology in ... crucial role in fostering the rapid production of ...
(Date:4/20/2014)... crop residue to make ethanol and other biofuels reduces ... gasoline, according to a study published today in the ... by a University of Nebraska-Lincoln team of researchers cast ... meet federal mandates to ramp up ethanol production and ... stalks, leaves and cobs in cornfields after harvest -- ...
(Date:4/18/2014)... have used techniques like X-ray crystallography and nuclear magnetic ... atomic structure of molecules, but such efforts have long ... quantities of a specific molecule and often in ordered ... all but impossible to peer into the structure of ... may soon be a thing of the past. ...
Breaking Biology News(10 mins):Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3MRI, on a molecular scale 2MRI, on a molecular scale 3
... DNA damage resets the cellular circadian clock, suggesting links ... the propensity for cancer. , Their work, reported June ... Science, implies a protective dimension for the biological clock ... a sweeping role in the rhythms and activities of ...
... Scientists from The University of Tokyo announce today that gibbons, ... not carry a major obesity gene that is present in ... is due to a genetic mis-shuffling event that occurred approximately ... the April issue of the scientific journal Genome Research ...
... containing platinum, Virginia Commonwealth University Massey Cancer Center researchers have ... in HIV and cancer. , The findings may help researchers ... targeting proteins known as zinc fingers. , In the May ... that a zinc finger protein, known as HIV NCp7, can ...
Cached Biology News:Novel connection found between biological clock and cancer 2Major obesity gene is 'lost in the shuffle' 2New protein target may advance design of HIV and cancer drugs 2
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
... Perm/Wash Buffer I can be used in ... to permeabilize cells and to serve as ... Because saponin-mediated cell permeabilization is a reversible ... cells in the presence of saponin during ...
Biology Products: